MedPath

Enlivex Therapeutics

Enlivex Therapeutics logo
๐Ÿ‡ฎ๐Ÿ‡ฑIsrael
Ownership
Public
Established
2005-10-01
Employees
49
Market Cap
-
Website
http://www.enlivex.com
Introduction

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Clinical Trials

7

Active:2
Completed:1

Trial Phases

2 Phases

Phase 1:5
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (7 trials with phase data)โ€ข Click on a phase to view related trials

Phase 1
5 (71.4%)
Phase 2
2 (28.6%)

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

Phase 1
Recruiting
Conditions
Arthritis, Psoriatic
Interventions
First Posted Date
2024-07-26
Last Posted Date
2025-04-23
Lead Sponsor
Enlivex Therapeutics Ltd.
Target Recruit Count
6
Registration Number
NCT06522035
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Meir Medical Center, Kfar Saba, Israel

๐Ÿ‡ฎ๐Ÿ‡ฑ

Rambam Medical Center, Haifa, Israel

๐Ÿ‡ฎ๐Ÿ‡ฑ

Carmel Medical Center, Haifa, Israel

and more 1 locations

Study of Intra-articular Allocetra in Knee Osteoarthritis

Phase 1
Active, not recruiting
Conditions
Osteoarthritis, Knee
Interventions
Other: Placebo
First Posted Date
2024-01-31
Last Posted Date
2025-04-23
Lead Sponsor
Enlivex Therapeutics Ltd.
Target Recruit Count
160
Registration Number
NCT06233474
Locations
๐Ÿ‡ฒ๐Ÿ‡ฉ

IMSP Institutul de Cardiologie, Chisinau, Moldova, Republic of

๐Ÿ‡ฒ๐Ÿ‡ฉ

Spitalul Clininc Republican "T. Mosneaga", Chisinau, Moldova, Republic of

๐Ÿ‡ฒ๐Ÿ‡ฉ

IMSP Sptalul Clinic Municipal "Sfanta Treime", Chisinau, Moldova, Republic of

and more 9 locations

A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)

Phase 2
Terminated
Conditions
Covid19
Interventions
Other: Placebo
First Posted Date
2021-06-11
Last Posted Date
2024-03-13
Lead Sponsor
Enlivex Therapeutics Ltd.
Target Recruit Count
12
Registration Number
NCT04922957
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Hadassah Ein Kerem Medical Center, Jerusalem, Israel

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

Phase 1
Conditions
Covid19
Interventions
First Posted Date
2020-12-09
Last Posted Date
2021-08-18
Lead Sponsor
Enlivex Therapeutics Ltd.
Target Recruit Count
18
Registration Number
NCT04659304

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

Phase 2
Active, not recruiting
Conditions
Community-acquired Pneumonia
Sepsis
Cholecystitis, Acute
Urinary Tract Infections
Cholangitis Acute
Intraabdominal Infections
Interventions
Other: Placebo
First Posted Date
2020-11-03
Last Posted Date
2024-03-13
Lead Sponsor
Enlivex Therapeutics Ltd.
Target Recruit Count
160
Registration Number
NCT04612413
Locations
๐Ÿ‡ง๐Ÿ‡ช

Clinique Saint-Pierre, Brussel, Belgium

๐Ÿ‡ง๐Ÿ‡ช

Saint-Luc Hospital University, Brussel, Belgium

๐Ÿ‡ง๐Ÿ‡ช

CHU de Charleroi, Charleroi, Belgium

and more 28 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.